Rapport Therapeutics, Inc.
RAPP
$14.77
-$0.16-1.07%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -40.14% | -55.34% | -125.11% | -- | -- |
| Total Depreciation and Amortization | 123.62% | 273.90% | 649.11% | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 18.69% | -1.21% | 211.01% | -- | -- |
| Change in Net Operating Assets | -410.02% | 471.08% | -191.10% | -- | -- |
| Cash from Operations | -53.11% | -68.65% | -138.50% | -- | -- |
| Capital Expenditure | 80.75% | 38.65% | -47.00% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 110.34% | 10.60% | -117.21% | -- | -- |
| Cash from Investing | 109.89% | 11.22% | -115.75% | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.99% | 530,273.33% | 294,540.74% | -- | -- |
| Repurchase of Common Stock | -34,775.00% | -34,775.00% | -34,750.00% | -- | -- |
| Issuance of Preferred Stock | -100.00% | -100.00% | -55.99% | -- | -- |
| Repurchase of Preferred Stock | -- | 66.28% | 66.28% | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 17.11% | 170.93% | 100.00% | -- | -- |
| Cash from Financing | -100.47% | 6.17% | 52.70% | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -279.23% | -39.66% | -134.13% | -- | -- |